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Abstract
Comprehensive characterization of a gene’s impact on phenotypes requires knowledge of the context of the gene. To
address this issue we introduce a systematic data integration method Candidate Genes and SNPs (CANGES) that links SNP
and linkage disequilibrium data to pathway- and protein-protein interaction information. It can be used as a knowledge
discovery tool for the search of disease associated causative variants from genome-wide studies as well as to generate new
hypotheses on synergistically functioning genes. We demonstrate the utility of CANGES by integrating pathway and
protein-protein interaction data to identify putative functional variants for (i) the p53 gene and (ii) three glioblastoma
multiforme (GBM) associated risk genes. For the GBM case, we further integrate the CANGES results with clinical and
genome-wide data for 209 GBM patients and identify genes having effects on GBM patient survival. Our results show that
selecting a focused set of genes can result in information beyond the traditional genome-wide association approaches.
Taken together, holistic approach to identify possible interacting genes and SNPs with CANGES provides a means to rapidly
identify networks for any set of genes and generate novel hypotheses. CANGES is available in http://csbi.ltdk.helsinki.fi/
CANGES/
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Introduction
Cellular functions are regulated by complex and multivariate
molecular regulatory networks. Complex diseases, such as cancers,
arise from alterations in these networks and thus contribution of
any single gene to disease risk or progression should be viewed in
the context of molecular networks [1,2]. Indeed, genome-wide
measurement technologies, such as gene and single nucleotide
polymorphism (SNP) microarrays, have provided an opportunity
to identify genes that are mutated or differentially expressed and
drive various diseases. In particular, SNP-arrays have been
powerful in genome-wide association (GWA) studies and have
resulted in several genetic loci or genes that are associated with
disease risk or poor prognosis [3–5]. As such candidate genes typically
affect cellular functions by altering signaling in regulatory
networks, it is crucial to comprehensively characterize these
regulatory networks.
We introduce a data integration workflow CANGES (Candidate
Genes and SNPs) to rapidly identify focal genes, i.e., genes that code
for proteins which interact or belong to the same molecular network
with a protein coded by a candidate gene. Additionally, CANGES is
able to identify central SNPs, i.e., genetic variations that are located in
the focal genes’ coding or regulatory regions, such as splice and 39
UTR sites (Table S1). Thus, central SNPs may affect protein
function and cause gene-gene and SNP-SNP interactions in the
regulatory network leading to increased risk or survival effects.
To identify focal genes, CANGES uses KEGG and Reactome
pathway databases [6,7] together with PINA protein-protein
interaction (PPI) database [8]. The focal genes are further queried
for their SNPs using ENSEMBL [9] and linkage disequilibrium
information from HapMap [10]. The impacts of non-synonymous
coding SNPs to protein functions are then predicted using
PolyPhen [11], PolyPhen-2 [12], SNPs3D [13] and SIFT [14].
Accordingly, CANGES can rapidly identify genes and SNPs
belonging to the same network of any set of genes.
CANGES integrates data from SNP, protein and linkage
disequilibrium databases and thus belongs to the meta-server class
of services [15]. Earlier meta-approaches have focused on
predicting SNP functions and linking them to GWA studies [16–
18], enriching SNPs with pathway- and functional annotations
[16,17], linking SNP annotations with PPI information [19],
collecting functional predictions for SNPs from a number of
sources for one SNP at a time [20] or collect and rank central
SNPs for specified genes and ontologies [21]. A unique feature in
CANGES is that, instead of just annotating genes, it takes an
advantage of the accumulated pathway and PPI information to
provide a comprehensive list of focal genes and central SNPs with
one batch query. For the more conventional use, CANGES
enables focal gene search based on the pathway name and SNP
retrieval for a custom gene list. CANGES also provides a means to
link central SNPs to tag-SNPs, which facilitates search for putative
disease causing alleles and enables integration of data from several
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SNP-arrays that typically use different sets of tag-SNPs. Each
CANGES query produces a downloadable result list, which
enables easy processing and comparison of the output. CANGES
runs on a freely available component-based bioinformatics work-
flow environment Anduril [22], which allows the use of CANGES
as a part of re-usable analysis workflows. Additionally, we have
created a web interface for smaller queries.
Results
CANGES workflow diagram, including modules, resources,
bioinformatics components and interfaces, is shown in Figure 1.
CANGES produces the results as Excel spreadsheets that enable
an easy sorting and filtering of the results. An example of an
CANGES produced result file is given in Table S2. Here, we
demonstrate the utility of CANGES with two case studies. The
first case study illustrates CANGES analysis for a single candidate
gene p53 and the second one focuses on assessing the context for
three genes reported in a recent glioblastoma GWA study.
Comprehensive catalogue of SNPs for the p53 associated
pathways and interactome
The gene p53 is one of the most studied genes in cancer biology.
However, the function and interplay of p53 with the other proteins
is still unclear. We used CANGES to provide the most
comprehensive set of proteins that function within the same
pathways with p53 or have direct PPI with p53 [Swiss-
Prot:P04637, Q9NP68] (Table S2). CANGES analysis produced
1,914 focal genes for p53 that were identified from databases as
illustrated in Figure 2A). Given the importance of p53 mutations in
Figure 1. Workflow of CANGES modules and components, resources and interfaces within each module. The input of the protein
module is a list of protein identifiers or pathway names. The output is a list of corresponding focal genes, i.e., genes that belong to the same
pathways with query protein or query pathway in KEGG or Reactome, or whose protein products interact with the query proteins. The resulted focal
genes are inputs for searching the central SNPs (SNP module) using ENSEMBL and HapMap. The central SNPs are first queried from ENSEMBL and
then the allele frequencies and tag-SNPs are fetched from a local HapMap database. The SNP module returns a list of central SNPs with their
annotations and tag-SNPs. The list of central SNPs is then passed for the evaluation module in which the SNPs are then further evaluated with four
methods that predict the functional effects of SNP to protein function.
doi:10.1371/journal.pone.0018636.g001
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cancer susceptibility and progression, we further queried central
SNPs for the p53 focal genes. This search resulted in 47,163
central SNPs and 3,465 tag-SNPs that tag 1,720 of the central
SNPs. The threshold for selecting the tag-SNPs was r2§0:8.
To further identify SNPs that putatively have functional effect at
the protein level, we analyzed the 47,163 central SNPs with four
methods. PolyPhen and PolyPhen-2 predicted 1,479 and 672
SNPs as functional with probable or possible damaging effect on
protein, respectively. SNPs3D predicted 2,000 SNPs being
functional, whereas SIFT resulted in 2,435 functional SNPs.
These prediction methods agreed for 158 SNPs (Table S3). Genes
associated with the set of 158 SNPs with predicted functional
effects at the protein level consists of several genes that are crucial
in pathogenesis, such as ATM, CDKN2A, BRCA1 and BRCA2. To
our knowledge, this catalogue is the most comprehensive list of
SNPs putatively affecting p53 mediated signaling.
Identification of survival associated SNPs in glioblastoma
multiforme
Glioblastoma multiforme (GBM) is grade IV glial originating
tumor type that responds poorly to all available therapeutic
regimens and has a median survival of one year [3]. In a recent
glioma GWA study Shete and colleagues identified low-penetrance
susceptibility loci harboring TERT (Swiss-Prot: O14746,
Q9UNR4, Q8NG38, Q9UBR6, Q9UNS6), CCDC26 (Swiss-Prot:
Q8TAB7), CDKN2A (Swiss-Prot: Q8N726, P42771, Q208B5,
Q5ZEY9, Q9UPB7, A7LNE7, A5X2G7, Q2MJK0), CDKN2B
(Swiss-Prot: P42772, Q5ZEY8, O15125, Q8NIA6, Q9UM95),
RTEL1 (Swiss-Prot: Q9BW37 Q9NZ71) and PHLDB1 (Swiss-Prot:
Q86UU1, B0YJ63, B0YJ65) with elevated risk of glioma [5]. We
queried focal genes using these six glioma-associated genes. TERT,
CDKN2B and CDKN2A were found in KEGG, Reactome or PINA.
These three genes resulted in a total of 1,346 focal genes
(Figure 2B), which were annotated for their central SNPs. This
resulted in 33,428 central SNPs, for which we found 2,657 tag-
SNPs having pair-wise correlation with a central SNP r2§0:8; 463
SNPs were both central and tag-SNPs totaling to 35,622 SNPs for
further analysis (Table S4).
We used The Cancer Genome Atlas (TCGA) GBM data set of
209 samples subjected to 550k SNP-array experiments to identify
SNPs associated with poor survival using Kaplan-Meier analysis
with log-rank test. We initially considered all 35,622 central and
tag-SNPs for the survival analysis. However, only 1,888 SNPs were
found from the TCGA genome-wide SNP-array for GBM. This
small number is due to the low number of central SNPs in the
SNP-arrays in general; here, 0.02% of the central SNPs were on
the array. We were able to estimate the survival effect for 995
central SNPs directly or through their tag-SNPs. Survival analysis
of the set of 1,888 SNPs resulted in 18 SNPs with a significant
survival effect. From these, eight were central SNPs, and 10 SNPs
further tag 18 central SNPs totaling to 26 central SNPs putatively
having survival impact.
We then mapped the set of 26 central SNPs with putative
survival effect to genes. The SNPs are located in 14 genes:
CAMK2D, CCNB1, CD82, CEP192, CLASP2, FLT3, KIF2B,
LAMA1, MTR, PML, PSMF1, SEC13, SGOL2 and SMAD5. The
lowest p-value (2:44|10{3) was observed for the tag-SNP
rs2275565 in the intronic region of the MTR gene. In addition,
the most significant odds ratio between homozygous genotypes
was calculated for the tag-SNP rs100192 (odds ratio 0.27 with p-
value 8:07|10{3) in the intronic region of the CENPH gene. This
SNP tags rs164390 in 59 UTR region of a gene G2/mitotic-
specific cyclin-B1 (CCNB1). Kaplan-Meier estimates for rs2275565
and rs100192 are illustrated in Figure 3, and the other figures with
CANGES output table are available in Figure S1 and Table S5.
Discussion
A number of individual cancer associated genetic variants have
been found recently, but the signaling-level context for these
variants has been challenging to establish. Finding genetic variants
causing functional effects to a protein network, which also contains
a risk or cancer-driving gene’s protein product, are of particular
interest as these are candidates for SNP-SNP or gene-gene
interactions. In order to obtain a comprehensive network for a set
of genes, there is a need to integrate several databases, such as PPI,
Figure 2. Distribution of the database sources. The database sources of focal genes for a) p53 and b) glioblastoma multiforme case study.
doi:10.1371/journal.pone.0018636.g002
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genomic and pathway repositories. CANGES is hypothesis
generating tool that provides a significant step forward in
obtaining a comprehensive view for a gene set. Furthermore,
CANGES is implemented to run on Anduril workflow environ-
ment [22], which allows for integration of several protein resources
and analysis approaches as exemplified in the glioblastoma
multiforme case study.
Many genome-wide SNP arrays, such as Illumina HumanHap
arrays, are designed so that the probes query for tag-SNPs instead
of central SNPs [23]. The use of tag-SNPs aims at maximizing the
amount of variation a SNP captures, which is desirable in many
GWA studies. It is, however, challenging to use tag-SNPs to
estimate the functional consequences of the observed variation.
CANGES compensates the tag-SNP designs by using the HapMap
Figure 3. Kaplan-Meier estimates and the number of cases of the genotype groups for the GBM survival analysis. Dashed lines
illustrate 0.95 confidence intervals for each group in the analysis. Panel a) rs2275565 is a tag-SNP to the coding SNP rs1805087 in the MTR gene. The
group of 11 homozygous cases with AA genotypes is combined with the heterozygous group. Panel b) rs100192 is a tag-SNP to a SNP rs164390 in 59
UTR of the CCNB1 gene.
doi:10.1371/journal.pone.0018636.g003
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database and producing a comprehensive list of SNPs in region
pinpointed by the tag-SNPs. Analysis with functionally designed
SNP-arrays such as Affymetrix Drug Metabolism Analysis
(DMET) array that contains 1,936 drug metabolism markers in
225 genes or Illumina GoldenGate chip, with approximately 1,500
user-chosen SNPs, target effectively genotypes of several central
SNPs that are more amenable to CANGES analysis. Recently
several intragenic SNPs have been associated with diseases. These
SNPs are usually not the causative variations but surrogate
markers indicating the region in which the causative mutation is
harbored [24]. Furthermore, the effect of intragenic SNPs to the
protein function is currently an unresolved problem. Therefore,
CANGES focuses on central SNPs while the intragenic SNPs are
discarded from the result lists to avoid dominance of a huge
number of the intragenic SNPs.
CANGES provides a means to integrate information from
several databases that are accessed through their programming
interfaces when such interface is provided. This allows the use of
the latest releases of the databases. CANGES may produce very
large result sets for queries including genes having a lot of
interactions or activity in signaling pathways. In such cases
CANGES analysis may take several hours to complete when
executed through the CANGES web interface. Therefore,
processing of large queries is more efficient through local
installations of CANGES than with the website. Furthermore, it
is also challenging to estimate the size of the result file because the
amount of data in the databases varies for different genes and
pathways. The p53 gene is a prime example of a well-studied gene
that produces a very large result set. On the other hand, only three
out of six GBM risk genes were found from the pathway- or PPI
databases.
Our case studies demonstrate that SNP-protein function
prediction tools resulted in widely dissimilar results. For example,
in the p53 case study, only PolyPhen-2 was able to predict that
rs1042522 is damaging. Even F-SNP, which uses 16 methods and
datasets to predict functional effects of SNP [20], was not able to
predict rs1042522 to be damaging (results not shown). The
rs1042522 variant causes an amino acid change (R72P) with
demonstrated functional consequences; the R72 variant is a
stronger and faster inducer of apoptosis than the 72P variant
[25,26] while the 72P variant binds more efficiently to iASPP, an
inhibitor of pro-apoptotic function of p53 [27]. The 72P variant
has been found to be more efficient in inducing cell-cycle arrest
[25] and DNA repair [28] than the R72 variant. The 72P variant
also predicts survival of breast cancer patients [29,30].
In our second case study we identified genes belonging to the
same pathway or directly interacting with protein products of
three glioma risk genes and further calculated survival estimates
for 1,888 SNPs in these genes. This analysis resulted in a SNP
(rs2275565) in the gene Methionine synthase (MTR) that encodes
the enzyme 5-methyltetrahydrofolate-homocysteine methyltrans-
ferase, which catalyzes methione biosynthesis. MTR was recently
identified as a cancer susceptibility gene regardless of environ-
mental factors [31]. Furthermore, rs2275565 is a tag-SNP for a
damaging SNP rs1805087, which was also found in the TCGA
dataset showing minor survival effects. Our results therefore
suggest that chromosomal region around rs2275565 and
rs1805087 is a candidate for harboring a causative variant for
the survival effect by MTR.
Our results further indicate that also rs100192, which is a tag-
SNP for rs164390 in 59 UTR region of a gene G2/mitotic-specific
cyclin-B1 (CCNB1), may have an impact on GBM survival. We
note that rs164390 itself was not found from the GBM dataset and
its effect on the survival could not be estimated directly. This is a
common situation in studies integrating data from different
cohorts with varying SNP-array designs; and the CANGES results
provide a means to rapidly integrate such data. Interestingly,
CCNB1 belongs to the same pathways with CDKN2A and CDKN2B
and is regulated by p53. An increase in the copy number in the
chromosomal region of CCNB1 has been shown to be associated
with an increase of the cell growth rate in glioma cell lines [32].
Furthermore, upregulation of CCNB1 along with other cell-cycle
genes indicates poor survival in various cancers [33], and
upregulation of CCNB1 alone is suggested to be a marker for a
poor prognosis in breast cancer [34], making CCNB1 an
interesting target candidate also in GBM. While it is not surprising
to identify to find 18 SNPs with a survival effect from a set of 1,888
SNPs, the two most interesting genes identified here were not be
detected in genome-wide context.
Both MTR and CCNB1 function in the p53 pathway, which is
altered in 87% of GBM cases [3]. MTR interacts with CDKN2A
[35] and CCNB1 is a response gene for p53 [36,37], which leads to
a pathway hypothesis illustrated in Figure 4. Though further
studies are required to validate the suggested roles of MTR and
CCNB1 in glioblastoma multiforme, our results demonstrate that
CANGES is able to produce experimentally testable hypotheses
that offer a solid ground for advanced analyses.
Methods
The CANGES data integration pipeline is divided into three
modules, 1) the protein module, 2) the SNP module and 3) the evaluation
module as illustrated in Figure 1. Each module can be run
individually, which enables four different options for use as
described in Table 1.
CANGES workflow
The protein module searches for focal genes from the pathway
databases KEGG [6] and Reactome [7], and the PPI database
PINA [8], using their programming interfaces. The input for the
protein module is a list of proteins or pathways, and the output is a
list of focal genes that are either on the search pathway or
interacting with at least one of the search proteins through direct
interaction or through the same pathway. In the case of the
protein list, the protein module searches for all the pathways and
PPIs for each protein and creates a list of focal genes from proteins
from the resulted pathways and interactions. In the case of the
pathway name list, the protein module uses proteins in the query
pathways as the list of focal genes.
The SNP module annotates central SNPs for the queried genes
from the ENSEMBL genome database [9]. The SNP module
excludes all SNPs that are annotated as upstream, downstream,
intronic, within non-coding gene or hgmd mutations in EN-
SEMBL (v. 59), resulting in the central SNPs for the each gene.
The SNP module also annotates each SNP with functional,
sequence and transcript information as well as information on
protein domains in the region of the SNP. A complete list of the
annotations in a result file is given in Table S1. We have
implemented two redundant interfaces to the ENSEMBL
database; the first interface uses BioMart [38] and the second
the ENSEMBL Perl. The BioMart interface is much faster than
Perl and is thus prioritized. It is, however, also more unstable and
the Perl interface allows CANGES to function in cases when
BioMart is not responding. The results from the BioMart and Perl
interfaces are essentially the same, except that the BioMart
implementation collects each SNP from all associated alternative
transcripts, while the Perl implementation uses only the first
transcript returned by the ENSEMBL database. To avoid
Data Integration Workflow
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time-consuming and redundant searches, the surrounding peptide
sequences are fetched only for one alternative transcript if the SNP
is located to the same position. The SNP module searches also
allele frequencies and tag-SNPs for each annotated SNP, using the
HapMap database version 3, draft 1 [10]. The tag-SNPs are
selected according to a minimum pair-wise correlation (r2)
between SNPs in the HapMap database with threshold or as
chosen by the user. The allele frequencies and the pair-wise
correlations are calculated using the Plink software [39]. The input
for the SNP module is a list of protein or gene identifiers, and the
output is a list of SNP annotations for each given identifier.
The evaluation module produces predictions for functional
effects of SNP to protein function for non-synonymous coding
SNPs, using four prediction tools: PolyPhen [11], PolyPhen-2
[12], SNPs3D [13] and SIFT [14]. PolyPhen and PolyPhen-2
produce predictions (benign, possibly damaging, probably damaging)
based on the rules regarding the SNPs effect on protein functional
sites, the protein structure and the presence of the same peptide
substitution in homologous sequences. PolyPhen may produce
several predictions for one SNP and all of the predictions are
included into the results. SNPs3D calculates scores for SNPs
using a protein structure stability model and a feature profile that
captures sequence conservation with a support vector machine
algorithm. Negative scores predict deleterious effects. The
CANGES evaluation module uses the lowest score from the
available SNPs3D scores for each SNP. SIFT’s predictions are
based on the probability of SNP’s peptide in homologous
sequences, and it considers peptide probability lower than 0.05
damaging for the protein function. SIFT gives a prediction for
both SNP’s optional peptide variants and the evaluation module
selects the lower value indicating more deleterious effect for the
prediction. For the predictions, we use local copies of pre-
calculated datasets: PolyPhen (54,574 SNPs) and PolyPhen-2
(32,534 SNPs) are from dbSNP build 126 and 130, respectively,
whereas SNPs3D uses dbSNP build 128 with 77,999 SNPs and
and it uses dbSNP build 129 (178,509 SNPs). The input of the
evaluation module is a list of SNP rs-identifiers and the output is
the predictions.
Survival calculations
The effects of GBM focal genes on patient survival were
calculated using 209 GBM patient blood samples subjected to
550k SNP-array from the TCGA data set [3]. The survival
analyses for all SNPs were conducted with the Kaplan-Meier
estimation method and log-rank test, and odds ratios were
estimated with logistic regression. In survival analysis we imputed
Figure 4. Pathway diagram showing the hypothetical positions
of the GBM survival associated genes MTR and CCNB1 in the
glioblastoma p53 pathway [3]. KEGG annotates CCNB1 to belong to
the p53 pathway together with CCNB2, CCNB3 and CDC2 [6]. In the
KEGG p53 signaling pathway, these are regulated by the genes SFN,
GADD45G, GADD45A and GADD45B, which constitute a subset of the
p53 target genes. In the KEGG glioma pathway, G2 arrest impairment is
annotated as one result of the altered p53 pathway activation [6].
doi:10.1371/journal.pone.0018636.g004
Table 1. Example use cases of CANGES.
CANGES use cases
Goal Input Databases Result
1. Create a set of focal genes or central SNPs
based on previously found interesting genes.
List of proteins KEGG, Reactome, PINA, ENSEMBL,
Hapmap, PolyPhen, SNPs3D, SIFT
A list of focal genes and their central
SNPs with SNP annotations.
2. Create a set of focal genes or SNPs based on
previously found interesting pathways.
List of pathway names KEGG, Reactome, PINA, ENSEMBL,
Hapmap, PolyPhen, SNPs3D, SIFT
A list of focal genes and their central
SNPs with SNP annotations.
3. Get central SNPs for a custom pathway or
a set of interesting genes.
List of genes ENSEMBL, Hapmap, PolyPhen,
SNPs3D, SIFT
A list of central SNPs with annotations.
4. Find predictions for a set of coding SNPs. List of genes PolyPhen, SNPs3D, SIFT A list of functional predictions for
coding SNPs.
The modular structure of CANGES enables selecting inputs, outputs to serve various research goals.
doi:10.1371/journal.pone.0018636.t001
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missing values to genotypes having confidence value v0:95,
filtered out SNPs with the frequency of missing genotypes w10%
or minor allele frequencyv10 % and set signal to noise ratiov5
as suggested by [40]. The Kaplan-Meier estimates may become
unreliable with small sample sizes. Therefore, we combined the
rare homozygous samples with the heterozygous samples when the
frequency of homozygotes fell below 10%. This conservative
criterion should ensure robust Kaplan-Meier estimates. The
combination is optional and the threshold can be assessed by the
user. Kaplan-Meier estimates with nominal p-values v0:01 were
considered as significant.
Availability and Future Directions
The CANGES workflow is available as a web service in http://
csbi.ltdk.helsinki.fi/CANGES/. The Anduril components are also
available at this site. Related databases and the Anduril workflow for
the survival analysis are available upon request. Future work focuses
on integrating SNP-protein function predictors when such become
available. We will also include more variation types from the
ENSEMBL database when their consequences on the gene products
can be estimated. One future direction of CANGES is to select
SNPs for customized high-throughput genotyping experiments.
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Figure S1 The Kaplan–Meier curves from the 16 SNPs
showing survival effect from the glioblastoma multi-
forme case study.
(PDF)
Table S1 The complete description of annotations from
both ENSEMBL Perl and BioMart interfaces.
(XLS)
Table S2 The list of proteins and their SNP annotations
(ENSEMBL Perl interface) of focal genes from the p53
case study.
(XLS)
Table S3 The list p53 focal genes’ coding SNPs that all
prediction methods in CANGES estimate of being
functional.
(XLS)
Table S4 The list of the central SNPs and their
annotations (ENSEMBL Perl interface) from the glio-
blastoma multiforme case study.
(XLS)
Table S5 The central SNPs from the glioblastoma
multiforme case study that show a survival effect either
itself or through tagSNPs. Columns from survival analysis are
the following: SurvivalMarker = the SNP for which survival is
estimated, Hetero OR = the odds ratio between heterozygous and
homozygous genotypes, Homo OR = the odds ratio between
homozygous genotypes, pvalue = the p-value.
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